| Literature DB >> 27334375 |
Mai Louise Grandsgaard Mikkelsen1, Rikard Ambrus2, James Edward Miles3, Helle Harding Poulsen3, Finn Borgbjerg Moltke4,5, Thomas Eriksen3.
Abstract
The objective of this review is to evaluate the existing literature with regard to the influence of propofol and remifentanil total intravenous anaesthesia (TIVA) on cerebral perfusion and oxygenation in healthy pigs. Anaesthesia has influence on cerebral haemodynamics and it is important not only in human but also in veterinary anaesthesia to preserve optimal regulation of cerebral haemodynamics. Propofol and remifentanil are widely used in neuroanaesthesia and are increasingly used in experimental animal studies. In translational models, the pig has advantages compared to small laboratory animals because of brain anatomy, metabolism, neurophysiological maturation, and cerebral haemodynamics. However, reported effects of propofol and remifentanil on cerebral perfusion and oxygenation in pigs have not been reviewed. An electronic search identified 99 articles in English. Title and abstract screening selected 29 articles for full-text evaluation of which 19 were excluded with reasons. Of the 10 peer-reviewed articles included for review, only three had propofol or remifentanil anaesthesia as the primary study objective and only two directly investigated the effect of anaesthesia on cerebral perfusion and oxygenation (CPO). The evidence evaluated in this systematic review is limited, not focused on propofol and remifentanil and possibly influenced by factors of potential importance for CPO assessment. In one study of healthy pigs, CPO measures were within normal ranges following propofol-remifentanil anaesthesia, and addition of a single remifentanil bolus did not affect regional cerebral oxygen saturation (rSO2). Even though the pool of evidence suggests that propofol and remifentanil alone or in combination have limited effects on CPO in healthy pigs, confirmative evidence is lacking.Entities:
Keywords: Animal model; Brain; Neuroanaesthesia; Oxygenation; Perfusion; Pig; Propofol; Remifentanil
Mesh:
Substances:
Year: 2016 PMID: 27334375 PMCID: PMC4917978 DOI: 10.1186/s13028-016-0223-6
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Target ranges for anaesthesia related cerebral perfusion and oxygenation measures in humans
| Target | Measure | Limits | Reference |
|---|---|---|---|
| CerAutoRega | mm Hg | 50–150 | [ |
| MAP | mm Hg | >80 | [ |
| CPP | mm Hg | 50–70 | [ |
| rSO2 | % | 60–80 | [ |
| SvjO2 | % | 50–75 | [ |
| brPO2 | mm Hg | 25–50 | [ |
| CBF | ml/min/100 g | 25–50 | [ |
| CarotidBF | ml/min | 275 ± 52 | [ |
MAP: mean arterial pressure; ICP: intracranial pressure; CPP: cerebral perfusion pressure; rSO : regional cerebral oxygen saturation; SvjO : jugular venous oxygen saturation; brPO : brain tissue partial pressure of oxygen; CBF: cerebral blood flow; CarotidBF: carotid blood flow
aUpper and lower limits for cerebral autoregulation—highest in newborn lowest in adults
Means and 95 % confidence levels of reported cerebral perfusion measures
| Study ID [reference] | n | Outcome | Measure | Mean | CI 95 % (LL) | CI 95 % (UL) |
|---|---|---|---|---|---|---|
| Boezaart [ | 10 | CBF | TPU | 44.7 | 29.2 | 60.2 |
| Lurie et al. [ | 22 | CarotidBF | ml/min | 119.4 | 101.8 | 136.9 |
| Silva et al. [ | 12 | SvjO2 | % | 82.7 | 77.0 | 88.3 |
| Silva et al. [ | 12 | SvjO2 | % | 79.0 | 73.9 | 84.1 |
| Srinivasan et al. [ | 13 | CPP | mm Hg | 73.6 | 67.0 | 80.2 |
| Yannopoulos et al. [ | 16 | CarotidBF | ml/min | 174.8 | 153.6 | 196.0 |
| Yannopoulos et al. [ | 16 | CPP | mm Hg | 68.0 | 61.6 | 74.4 |
| Yannopoulos et al. [ | 12 | CPP | mm Hg | 74.0 | 64.6 | 83.4 |
| Yannopoulos et al. [ | 16 | CPP | mm Hg | 74.8 | 67.2 | 82.3 |
n: number of animals; CI: confidence interval; LL: lower limit; UL: upper limit; CBF: cerebral blood blow; CarotidBF: carotid blood flow; SvjO2: jugular venous haemoglobinoxygen saturation; CPP: cerebral perfusion pressure
Summary of the effects of propofol and remifentanil on cerebral blood flow and cerebral autoregulation in selected animal species used in experimental neuroscience
| Species | CBF | CA | References | |||
|---|---|---|---|---|---|---|
| P | R | PR | P | PR | ||
| Humans | ↓ | ↑↓* | ↓ | Preserved | Preserved | [ |
| Dog | ↓ | ↓ | • | Preserved | • | [ |
| Rabbit | ↓ | • | • | • | • | [ |
| Rat | ↓ | • | • | Preserved | • | [ |
CBF: cerebral blood flow; CA: cerebral autoregulation; P: propofol; R: remifentanil; PR: propofol-remifentanil combination; ↑: increased; ↓: decreased; •: uncertain; *: dose dependant
Fig. 1PRISMA flow chart, Based on [102]
Anaesthesia relevant data
| Study ID [reference] | Premedication. drug (dosea) | Propofol doseb (induction/maintenance) | Remifentanil dose |
|---|---|---|---|
| Boezaart [ | Ketamine (10 mg/kg im) Pancuronium (0.1 mg/kg) | 2.0 mg/kg/3.0 mg/kg/h | 0.35 mikrogram/kg/min |
| Kajimoto et al. [ | Ketamine (33 mg/kg im) xylazine (2 mg/kg im) | 1.0–2.0 mg/kg/15.0 mg/kg/h for 15 min then 12.0/mg/h for 45 min then 9.0 mg/kg/h for 60 min then 7.5 mg/kg for 120 min | Not used |
| Lurie et al. [ | Ketamine (21.9–25.0 mg/kg im) | 2.3 mg/kg + 1.0 mg/kg/9.6 mg/kg/h | Not used |
| Navarro et al. [ | Ketamine/Telazol/xylazine im (not reported) | 1.5 mg/kg/9.0 mg/kg/h | Not used |
| Silva et al. [ | Azaperone (4 mg/kg im) | 4.0 mg/kg/15.0 mg/kg/h | 0.3 mikrogram/kg/min followed by 0.2 mikrogram/kg/min |
| Silva et al. [ | Azaperone (4 mg/kg im) | 4.0 mg/kg/15.0 mg/kg/h | 0.3 mikrogram/kg/min + 5 mikrogram/kg bolus |
| Srinivasan et al. [ | Ketamine (21.2–31.3 mg/kg im)c | 2.0–3.0 mg/kg/9.6 mg/kg | Not used |
| Yannopoulos et al. [ | Ketamine (23.0–23.7 mg/kg im) | 1.0 mg/kg/9.6 mg/kg/h | Not used |
| Yannopoulos et al. [ | Ketamine (21.7–23.5 mg/kg im) | 2.0 mg/kg/9.6 mg/kg/h | Not used |
| Yannopoulos et al. [ | Ketamine (25.6–30.3 mg/kg im) | 2.3 mg/kg/9.6 mg/kg/h | Not used |
aDoses are calculated based on animal weight
bDoses reported as mikrogram/kg/min are converted to mg/kg/h for easier comparison
cCalculated under the assumption that lowest dose was given to animals with lowest weight
Animal and publication relevant data
| Study ID [reference] | Animal intervention study | Random sequence allocation | n | Gender/pig breed | Weight (kg)a | Age in weeks |
|---|---|---|---|---|---|---|
| Boezaart [ | 1 group | NA | 10 | Female/pigs | 22–28 | 8–9b |
| Kajimoto et al. [ | 2 groups | No | 14 | Male/yorkshire | 7.8–14.5 | 4–6c |
| Lurie et al. [ | 2 groups | Yes | 22 | Female/farm pigs | 30.4 ± 1.3 | 9–11b |
| Navarro et al. [ | 1 group | NA | 6 | Female/swine | 21.5–92.8 | 8–21b |
| Silva et al. [ | 2 groups | Yes | 12 | Male/large white | 27.0 ± 3.6 | 12d |
| Silva et al. [ | 1 group | NA | 12 | Male/Large white | 26.2 ± 3.6 | 12d |
| Srinivasan et al. [ | 1 group | NA | 13 | Female/domestic farm pigs | 16–33 | 12–16 |
| Yannopoulos et al. [ | 2 groups | Yes | 16 | Female/farm pigs | 30 ± 0.5 | 10–11b |
| Yannopoulos et al. [ | 2 groups | No | 12 | Female/yorkshire-farm cross | 31 ± 1.2 | 10–11b |
| Yannopoulos et al. [ | 2 groups | Yes | 16 | Female/farm pigs | 25.2 ± 2.1 | 8–9b |
n: number of animals; NA: not applicable
aMean ± SD or upper and lower limits
bAge in weeks estimated from weight post hoc if not reported
cReported as 27–41 days
dReported as 3 months
Means and 95 % confidence intervals of reported MAP
| Study ID [reference] | n | Outcome | Measure | Mean | CI 95 % (LL) | CI 95 % (UL) |
|---|---|---|---|---|---|---|
| Boezaart [ | 10 | MAP | mm Hg | 89.0 | 82.6 | 95.4 |
| Kajimoto et al. [ | 7 | MAP | mm Hg | 69.0 | 63.1 | 74.9 |
| Lurie et al. [ | 22 | MAP | mm Hg | 91.8 | 85.3 | 98.2 |
| Navarro et al. [ | 6 | MAP | mm Hg | Range | 70.0 | 110.0 |
| Silva et al. [ | 12 | MAP | mm Hg | 72.7 | 67.4 | 78.0 |
| Silva et al. [ | 12 | MAP | mm Hg | 73.0 | 67.3 | 78.7 |
| Yannopoulos et al. [ | 16 | MAP | mm Hg | 81.0 | 73.9 | 88.1 |
| Yannopoulos et al. [ | 12 | MAP | mm Hg | 90.0 | 81.2 | 98.8 |
| Yannopoulos et al. [ | 16 | MAPa | mm Hg | 90.1 | 83.8 | 96.4 |
n: number of animals; MAP: mean arterial pressure; CI: confidence interval; LL: lower limit; UL: upper limit
aCalculated from systolic and diastolic blood pressure
Means and 95 % confidence intervals of reported cerebral oxygenation measures
| Study ID [reference] | n | Outcome | Measure | Mean | CI 95 % (LL) | CI 95 % (UL) |
|---|---|---|---|---|---|---|
| Kajimoto et al. [ | 7 | rSO2 | % | 51.0 | 47.1 | 54.9 |
| Lurie et al. [ | 22 | brPO2a | mm Hg | 13.2 | 9.9 | 16.5 |
| Navarro et al. [ | 6 | rSO2 | % | Range | 65.0 | 80.0 |
| Silva et al. [ | 12 | rSO2 | % | 62.3 | 58.6 | 65.9 |
| Silva et al. [ | 12 | rSO2 | % | 65.0 | 61.6 | 68.4 |
n: number of animals; CI: confidence interval; LL: lower limit; UL: upper limit; rSO2: regional cerebral oxygene saturation; brPO2: brain tissue partial pressure of oxygen
aExtrapolated from graph